2011 - Transplantomics and Biomarkers in Transplantation


Techniques Showcase Presentation

1.2 - HLA-High Throughput Sequencing

Presenter: Birgitte B., Simen, Branford, CT, USA
Authors: Birgitte B. Simen


HLA-High Throughput Sequencing

Birgitte B. Simen, R&D Molecular Biology, Roche, USA

Learning Objectives:

Upon the completion of this presentation the participants will be able to:

1. Explain why setting phase is important for HLA typing
2. Contrast population-based and high throughput clonal sequencing
3. Recognize the utility of full-length clonal exon sequencing for genotyping

The high degree of polymorphism at human leukocyte antigen (HLA) class I and class II loci makes high-resolution HLA typing challenging. Current typing methods, including population-based (Sanger) sequencing, yield ambiguous typing results because of incomplete genomic coverage and inability to set phase for HLA allele determination. The long sequencing reads from Roche 454 Life Sciences’ next generation sequencing system coupled with Conexio ATF software provides very high resolution HLA genotyping. High-throughput genotyping can be achieved by use of primers with multiplex identifier (MID) tags to allow pooling of the amplicons generated from different samples prior to sequencing.Data from both the high throughput GS FLX System and the benchtop GS Junior System will be presented.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi